Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2009

View Archived Issues

Novel anti-EGFR antibody GA-201 active in tumor models

P53-armed oncolytic adenovirus CGCT-04 induces apoptosis in cancer cells

Studies explore pharmacokinetics, antitumor activity of novel formulation of SN-38

Roche reviews Q1 activity

Speedel describes novel renin inhibitors as antihypertensive agents

Ark Therapeutics enrolls first patient into phase III study of Trinam in end-stage renal disease

SemBioSys' reports results from preclinical studies of plant-derived Apo AI(Milano)

Prospect Therapeutics to action off assets in June 2009

Rexahn enrolls 50% of patients in phase IIa trial of Serdaxin in MDD

Albert Einstein School of Medicine to conduct study of nanoviricide in HSV keratitis

Koronis SAB confirms positive results from studies of HIV drug KP-1461

Celator and Cephalon enter agreement in drug development and life-cycle management

Merck & Co. discovers novel quinolizidinone compounds for the treatment of Alzheimer's disease

Novartis presents novel ALK5 inhibitors for the treatment of liver fibrosis

Ferrer claims melatonin receptor agonists for the treatment of sleep disorders

Schering-Plough describes novel kinesin spindle protein inhibitors for cancer treatment

Oritavancin efficacy detailed in ECCMID presentations

Novel monobactam antibiotic BAL-0030072 shows potent activity against multiresistant bacteria

Aerie Pharmaceuticals reports on discovery and preclinical activity of glaucoma agent AR-12286

Fusion protein KH-902 well tolerated in patients with choroidal neovascularization

Vical advances H1N1 pandemic influenza (swine flu) vaccine program

FDA accepts for review SkyePharma's NDA for Flutiform in persistent asthma

Johnson & Johnson to acquire Cougar Biotechnology

Health Canada approves PolyMedix's CTA for phase Ib clinical study of PMX-30063

Genzyme submits information requested by FDA for Lumizyme

Human Genome Sciences submits BLA to FDA for ABthrax inhalation anthrax treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...